Evidence map›Paper›PMID 39044049›Full record

ReviewAAPS PharmSciTech2024

Enhanced Skin Penetration and Efficacy: First and Second Generation Lipoidal Nanocarriers in Skin Cancer Therapy.

Palak Sharma, Shreya Kaul, Neha Jain, Manisha Pandey, Upendra Nagaich

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Palak SharmaDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Uttar Pradesh, 201301, Noida, India.
Shreya KaulDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Uttar Pradesh, 201301, Noida, India. skaul@amity.edu.ORCID http://orcid.org/0000-0002-8540-3612
Neha JainDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Uttar Pradesh, 201301, Noida, India. njain1@amity.edu.ORCID http://orcid.org/0000-0003-3827-5598
Manisha PandeyDepartment of Pharmaceutical Sciences, Central University of Haryana, Mahendergarh, Haryana, India.ORCID http://orcid.org/0000-0002-8249-9743
Upendra NagaichCenter for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Science, Chennai, India.ORCID http://orcid.org/0000-0003-0076-6885

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin carcinoma remains one of the most widespread forms of cancer, and its global impact continues to increase. Basal cell carcinoma, melanoma, and squamous cell carcinoma are three kinds of cutaneous carcinomas depending upon occurrence and severity. The invasive nature of skin cancer, the limited effectiveness of current therapy techniques, and constraints to efficient systems for drug delivery are difficulties linked with the treatment of skin carcinoma. In the present era, the delivery of drugs has found a new and exciting horizon in the realm of nanotechnology, which presents inventive solutions to the problems posed by traditional therapeutic procedures for skin cancer management. Lipid-based nanocarriers like solid lipid nanoparticles and nanostructured lipid carriers have attracted a substantial focus in recent years owing to their capability to improve the drug's site-specific delivery, enhancing systemic availability, and thus its effectiveness. Due to their distinct structural and functional characteristics, these nanocarriers can deliver a range of medications, such as peptides, nucleic acids, and chemotherapeutics, via different biological barriers, such as the skin. In this review, an effort was made to present the mechanism of lipid nanocarrier permeation via cancerous skin. In addition, recent research advances in lipid nanocarriers have also been discussed with the help of in vitro cell lines and preclinical studies. Being a nano size, their limitations and toxicity aspects in living systems have also been elaborated.

Indexed as

Antineoplastic AgentsDrug CarriersLipidsNanoparticlesSkin NeoplasmsAdministration, CutaneousAnimalsDrug Delivery SystemsHumansSkinSkin AbsorptionAntineoplastic AgentsDrug CarriersLipidsbasal cell carcinomamelanomananostructured lipid carrierssolid lipid nanoparticlessquamous cell carcinoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.